Sativex, researched and developed by GW Pharmaceuticals, has now been approved in the UK. It has also been approved for use in Spain, Germany, Denmark, New Zealand and Canada.
Sativex oromucosal spray is available on the British National Health Service and, in some cases, is fully funded by the Primary Care Trust (PCT) local to the area a patient is in. The maximum a patient may have is one prescription per week. A prescription contains 3 x 10ml vials of Sativex.
Although currently used as an 'add-on' treatment, patients using Sativex are finding it to be a very effective, disease modifying medicine. If existing medicine is not effective or causing a patient to suffer unpleasant side effects, it may be to their advantage to request Sativex through their doctor or neurologist.
A patient may also find an advantage in providing their doctor or neurologist with the latest information as many PCTs are still referring to old reports. Accurate information can be obtained from the GW Pharmaceuticals website here.
IACM Conference 2013
7th Conference on Cannabinoids in Medicine
27-28 September 2013
Holiday Inn, Cologne, Germany.
6th European Workshop on Cannabinoids
18-20 April 2013
Trinity College Dublin, Ireland
The University of British Columbia in partnership with the ICRS and the CCIC will organize “Cannabinoids in Clinical Practice” on 21 June 2013, a full day continuing medical education (CME) event.